Portfolio concentration
As of April 30, 2026 · N-PORT
Holdings
61
Top-10 weight
42.03%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
13
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
912.7
Holdings
As of April 30, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | US ULTRA BOND CBT Sep25 | — | 246,000 | $246.00K | 7.30% |
| 2 | US ULTRA BOND CBT Sep25 | — | 210,000 | $210.00K | 6.23% |
| 3 | US ULTRA BOND CBT Sep25 | — | 185,000 | $185.00K | 5.49% |
| 4 | US ULTRA BOND CBT Sep25 | — | 122,000 | $122.00K | 3.62% |
| 5 | ORGANON & CO | — | 6,937 | $91.92K | 2.73% |
| 6 | US ULTRA BOND CBT Sep25 | — | 71,000 | $71.00K | 2.11% |
| 7 | CORCEPT THERAPEUTICS INC | — | 1,316 | $61.22K | 1.82% |
| 8 | ENLIVEN THERAPEUTICS INC | — | 1,446 | $59.62K | 1.77% |
| 9 | AXSOME THERAPEUTICS INC | — | 278 | $57.75K | 1.71% |
| 10 | OMEROS CORP | — | 3,722 | $54.34K | 1.61% |
| 11 | PERRIGO CO PLC | — | 4,526 | $53.59K | 1.59% |
| 12 | DEFINIUM THERAPEUTICS INC | — | 2,383 | $52.14K | 1.55% |
| 13 | NEKTAR THERAPEUTICS | — | 605 | $51.45K | 1.53% |
| 14 | TREVI THERAPEUTICS INC | — | 3,718 | $51.16K | 1.52% |
| 15 | TERNS PHARMACEUTICALS INC | — | 949 | $50.23K | 1.49% |
| 16 | INDIVIOR PHARMACEUTICALS INC | — | 1,352 | $49.73K | 1.48% |
| 17 | PACIRA BIOSCIENCES INC | — | 1,945 | $49.58K | 1.47% |
| 18 | HARROW INC | — | 1,202 | $48.72K | 1.45% |
| 19 | JAZZ PHARMACEUTI | — | 239 | $48.52K | 1.44% |
| 20 | HARMONY BIOSCIENCES HOLDINGS INC | — | 1,542 | $48.20K | 1.43% |
| 21 | ROYALTY PHARMA-A | — | 951 | $47.64K | 1.41% |
| 22 | AMYLYX PHARMACEUTICALS INC | — | 2,974 | $47.58K | 1.41% |
| 23 | VIATRIS INC | — | 3,178 | $47.48K | 1.41% |
| 24 | CRINETICS PHARMACEUTICALS INC | — | 1,201 | $46.57K | 1.38% |
| 25 | ANI PHARMACEUTICALS INC | — | 582 | $46.24K | 1.37% |
| 26 | LIGAND PHARMACEUTICALS | — | 201 | $46.12K | 1.37% |
| 27 | MBX BIOSCIENCES INC | — | 1,510 | $45.63K | 1.35% |
| 28 | INNOVIVA INC | — | 1,980 | $45.52K | 1.35% |
| 29 | LIQUIDIA TECHNOLOGIES INC | — | 1,151 | $45.13K | 1.34% |
| 30 | AMNEAL PHARM INC | — | 3,493 | $44.95K | 1.33% |
| 31 | XERIS BIOPHARMA HOLDINGS INC | — | 7,337 | $44.94K | 1.33% |
| 32 | BRISTOL-MYERS SQUIBB CO | — | 740 | $44.84K | 1.33% |
| 33 | EDGEWISE THERAPEUTICS INC | — | 1,433 | $44.37K | 1.32% |
| 34 | OCULAR THERAPEUTIX INC | — | 4,673 | $43.79K | 1.30% |
| 35 | PFIZER INC | — | 1,626 | $43.41K | 1.29% |
| 36 | NUVATION BIO INC | — | 9,673 | $43.04K | 1.28% |
| 37 | ZOETIS INC CL A | — | 371 | $42.65K | 1.27% |
| 38 | ELANCO ANIMAL HEALTH INC | — | 1,893 | $42.35K | 1.26% |
| 39 | JOHNSON&JOHNSON | — | 183 | $42.06K | 1.25% |
| 40 | COLLEGIUM PHARMACEUTICAL INC | — | 1,246 | $42.03K | 1.25% |
| 41 | US ULTRA BOND CBT Sep25 | — | 42,000 | $42.00K | 1.25% |
| 42 | MERCK & CO | — | 382 | $41.71K | 1.24% |
| 43 | ALUMIS INC | — | 1,686 | $41.63K | 1.24% |
| 44 | LILLY ELI and CO | — | 44 | $41.12K | 1.22% |
| 45 | TARSUS PHARMACEUTICALS INC | — | 635 | $40.39K | 1.20% |
| 46 | SUPERNUS PHARMACEUTICALS INC | — | 834 | $40.03K | 1.19% |
| 47 | PHIBRO ANIMAL HEALTH CORP CL A | — | 749 | $39.83K | 1.18% |
| 48 | EYEPOINT PHARMACEUTICALS INC | — | 2,976 | $39.28K | 1.17% |
| 49 | PRESTIGE CONSUMER HEALTHCARE INC | — | 685 | $38.58K | 1.14% |
| 50 | AMPHASTAR PHARMACEUTICALS INC | — | 1,712 | $37.60K | 1.12% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.